- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06076798
Clinical Performance of AFGen1
Clinical Performance of the AFGen1 Device Over a 7-day Period
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary purpose of this study is to demonstrate the ECG signal acquired by the AFGen1 device is of adequate quality and is suitable to support its intended use for the detection of Afib. This will be evaluated by comparing the ECG data acquired by AFGen1 to that acquired by an FDA cleared 12-lead ECG device. The study will also seek to demonstrate that there is no degradation in the quality of the ECG signal it acquires over the maximum 7-day wear period that it can be prescribed for use.
The secondary purpose of this study is to confirm the adhesive performance of the device is appropriate to support its intended use per the requirements of sections 4.4 and 5.4 of ANSI AAMI EC12-1 .
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Tim J Bahney, BS
- Phone Number: 503-327-3806
- Email: Tim.Bahney@trivirumhealth.com
Study Locations
-
-
California
-
San Diego, California, United States, 92110
- 4927 Lillian Street
-
Contact:
- Cynthia Cadwell, MS BSN
- Phone Number: 858-775-7372
- Email: cadwellconsulting@yahoo.com
-
Principal Investigator:
- Cynthia M Cadwell, MS BSN
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
1. 18+ willing to sign the consent form
Exclusion Criteria:
- Implanted pacemakers
- Implanted cardioverter defibrillators
- Implanted cardiac resynchronization devices
- Potential life-threatening arrythmias
- Physical or mental health conditions that would prevent the person from being able to follow instructions regarding participation in the study
- Open wounds, abraded or irritated skin at the application site
- Planned to undergo a MRI during the course of the study duration
- Known or suspected to be pregnant
- Student or employee of TriVirum
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Wear AFGen1
Wear AFGen1 for 7 days.
ECG co-measurement with 12 lead device at start and end of wear period
|
Measure ECG with 12 lead device at same time that AFGen1 is monitoring ECG
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quantitative Evaluation
Time Frame: 7 days
|
For the quantitative evaluation of the mean and standard deviation of the QRS amplitude, duration, and timing correlations for all study subjects and for the end of the wear period for those relevant subjects, the mean correlation coefficient must be greater than 0.95 and standard deviation must be less than 0.05 to validate a 95% confidence interval with significant factor of assurance. validate a 95% confidence interval with significant factor of assurance. |
7 days
|
Adhesive performance
Time Frame: 7 days
|
For the adhesive performance element of the study, the overall average wear time for the device must be greater than 5-days.
|
7 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 130-0006P
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation
Clinical Trials on ECG co-measurement
-
TriVirum, Inc.Active, not recruiting
-
WithingsUnknownCardiovascular Diseases | Atrial Fibrillation | Arrhythmias, CardiacFrance
-
WithingsUnknownAtrial FibrillationFrance
-
University Hospital, Basel, SwitzerlandEuropean Union; Preventicus GmbHRecruitingAtrial FibrillationHungary, Germany, Greece, Netherlands, Poland, Switzerland
-
University Hospital BirminghamNot yet recruiting
-
Chris Hani Baragwanath Academic HospitalMasimo CorporationCompletedCritically Ill Black PatientsSouth Africa
-
PulseOn OyTAYS Sydänkeskus Oy; Atostek OyCompleted
-
University National Heart HospitalRecruitingIschaemic Heart DiseaseBulgaria
-
Groupe Hospitalier Mutualiste de GrenobleTerminatedBenefit of Systematic Proposition of Nicotine Substitution for Patients Undergoing Surgery (PATCHIR)Smoking CessationFrance
-
Nik SpinthakisDr Guy HaywoodRecruitingAtrial Fibrillation RecurrentUnited Kingdom